However, unfortunately, because the number of patients with HER2-positive or triple-negative breast cancer is too small, meaningful analysis cannot be carried out in these subtypes (electronic supplementrary Figs. 3, 4 and 5). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.